Journal article
Enzalutamide with standard first-line therapy in metastatic prostate cancer
ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, X Coskinas, M Frydenberg, WE Hague, LG Horvath, AM Joshua, NJ Lawrence, G Marx, J McCaffrey, R McDermott, M McJannett, SA North, F Parnis, W Parulekar, DW Pook Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2019
Abstract
BACKGROUND Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with castration-resistant prostate cancer. It is not known whether adding enzalutamide to testosterone suppression, with or without early docetaxel, will improve survival in men with metastatic, hormone-sensitive prostate cancer. METHODS In this open-label, randomized, phase 3 trial, we assigned patients to receive testosterone suppression plus either open-label enzalutamide or a standard nonsteroidal antiandrogen therapy (standard-care group). The primary end point was overall survival. Secondary end points included progression-free survival as determined by the prostate-specif..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
Funded by Astellas Scientific and Medical Affairs and others; ENZAMET (ANZUP 1304) ANZCTR number, ACTRN12614000110684; ClinicalTrials.gov number, NCT02446405; and EU Clinical Trials Register number, 2014-003190-42.